Kiora Pharmaceuticals is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. This is self-described.

Kiora Pharmaceuticals

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Apple Mobile Web Clips Icon

Google Font API

Google Maps

WordPress

Font Awesome

Business Management

Brian Strem

Chief Development Officer

Eric Daniels

VP Clinical Operations

Angela Dentiste

Executive Vice President of Finance

Melissa Tosca

Director Sales Training and Development

James Elliott

Associate Director HR / Marketing Communications

Kimberly Daniels

Controller

Tara Pleickhardt

Senior Director, Corporate Development

Tj Lyons

District Sales Manager

Johnny Rasberry

Manufacturing Manager

Paul Mueller

Thomas Hancock

Mounia Chaoui

Praveen Tyle

Stephen From

President and CEO

Sarah Romano

Chief Financial Officer

Brenda Mann

VP, Research & Development

Alain Maiore

Director

Executive Chairman

Morton Goldberg

Chairman

Stefan Sperl

Executive Vice President CMC and Operations

United States Public Companies With Less Than $10M in Revenue

Biotechnology Companies (Top 10K)

Companies That Exited in 2021 (Top 10K)

Western US Companies (Top 10K)

Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.

Post-IPO Equity - Kiora Pharmaceuticals

Armistice Capital

Post-IPO Debt - Kiora Pharmaceuticals

Debt Financing - Kiora Pharmaceuticals

Series D - Kiora Pharmaceuticals

Salt Lake City

Utah

United States

North America

Kiora Pharmaceuticals target ajusted to $54 from $6 at Ladenburg

Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Kiora Pharmaceuticals Inc trading halted, news pending

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain ...

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Pharmaceuticals files to sell 76.53M shares of common stock for holders

A molecular photoswitch designed to restore vision by targeting retinal ganglion cells, turning them into light-sensing cells to bypass degenerated photoreceptors in inherited retinal diseases.

A DHODH inhibitor developed for treating non-infectious uveitis, reducing intraocular inflammation and improving visual acuity through intravitreal injection.

A compound from the KIO-100 family formulated for ocular surface inflammation, demonstrating safety and significant improvements in conjunctival hyperemia in clinical trials.

South Korea

Asia

Philippines

United Kingdom

Europe

Ukraine

HTML5

GoDaddy Premium DNS

F5 NGINX

Gravity Forms

Wordpress

Adobe Fonts

Google Analytics

jQuery

Fonts.com

Google Fonts

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Kiora Pharmaceuticals, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 19, 2024 5:53 AM	652ecc1e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 5:53 AM	77709ca5
crunchbase trigger	general	Nov 19, 2024 5:53 AM	f8cf69a3
crunchbase profile	general	Nov 19, 2024 11:45 PM	f53b5d2d
li profile	general	Nov 19, 2024 5:53 AM	840212a1
translate crunchbase fundingrounds	general	Nov 20, 2024 12:30 AM	ab4af9bf
peers	general	Nov 19, 2024 5:53 AM	7e6b1f25
news basic	general	Nov 19, 2024 5:53 AM	ccbda71e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:KIORAPHARMA

Kiora Pharmaceuticals

Last Close

3.45

21/11 21:00

Market Cap

12.98M

Beta: -

Volume Today

2.94K

Avg: -